ROP Roper Technologies, Inc.

CTSH vs. ROP: Which Stock Is the Better Value Option?

Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types. Roche agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT-388) reported positive Phase 2 results in type 2 diabetes and...

A fat dividend yield can signal generosity or a countdown clock, and retirees who chase the wrong one lose twice when the payout finally breaks. Four tests separate the durable payers from the traps before the cut arrives.

Most dividend growth watchlists stop at consumer staples brands you already know, but three industrial compounders have quietly raised their payouts every year for over a quarter century while making things most investors never think about.

Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question for you now is how much of that clinical momentum is already reflected in the price. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current...

Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than...

Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio’s label to patients who have received at least one prior systemic therapy. Roche highlighted that the Lunsumio and lenalidomide combination is designed for outpatient administration, aiming to ease capacity pressure on hospitals. The CELESTIMO outcome for...

Roper's Application Software segment is powering growth with rising SaaS adoption, recurring revenue strength and GenAI innovation across key businesses.

Despite summer insider selling, Roper Technologies shows strong Q2 fundamentals, raised guidance, buybacks, healthy balance sheet, and analyst and institutional support driving its stock rebound.

Roper Technologies has notably underperformed the Dow over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Roche Holding (SWX:ROP) has been back in focus after Treeline Biosciences agreed to a clinical trial collaboration that combines TLN-121 with Roche bispecific antibodies glofitamab and mosunetuzumab for B-cell lymphomas. Roche Holding shares trade at CHF357.0, with a 90-day share price return of 10.63% and a year-to-date share price return of 9.68%. The 1-year total shareholder return of 34.18% points to momentum that has built alongside a steady stream of oncology and diagnostics...

Roche Holding stock has delivered a solid multi year gain, yet the valuation signals are more mixed, which leaves investors weighing a strong price record against a less clear cut verdict on how cheap the shares really are. After a 3 year climb, the stock now screens as neither an obvious bargain nor clearly expensive. Roche Holding has returned about 54.2% over the past 3 years, which puts extra focus on whether that share price performance already reflects most of the good news in the...

Roche Holding (SWX:ROP) announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell lymphomas. The partners plan to evaluate advanced immune based treatments aimed at improving options for lymphoma patients. Roche received FDA clearance for its Elecsys pTau217 blood test as the first single biomarker assay to help both rule in and rule out amyloid pathology in Alzheimer’s disease. The Elecsys pTau217 test is intended to support clinicians in earlier...

Some dividend stocks boast decades of unbroken raise streaks yet leave income investors with almost nothing to show for it. These three companies sit in that strange category, and the tension between their legendary consistency and their near-invisible payouts reveals something important about what a dividend streak actually means.

Roche Holding (SWX:ROP) received FDA approval for its Elecsys pTau217 blood test for Alzheimer's disease in the U.S. The Elecsys pTau217 test is designed to identify amyloid pathology using a blood sample, widening access to dementia diagnostics across U.S. labs. The FDA also cleared expanded use of Roche's PATHWAY HER2 and VENTANA HER2 Dual ISH tests in metastatic gastroesophageal cancers. These approvals broaden options for HER2 testing in cancer care and support more tailored treatment...

Cognizant (CTSH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CoStar (CSGP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Genentech’s plan to invest $750 million in a new device fill finish facility in Hillsboro, Oregon, has put Roche Holding (SWX:ROP) back in focus for investors watching its U.S. manufacturing footprint. See our latest analysis for Roche Holding. Roche Holding’s recent manufacturing announcements have landed against a strong run in the stock, with a 13.0% 1 month share price return and a 15.4% year to date share price return, while the 1 year total shareholder return of 48.0% points to building...

Roche Holding stock has delivered a 58.5% return over the past three years, yet the current valuation checks give a more mixed read on how much upside may be left in the price. Roche Holding's 58.5% three year return highlights that shareholders have already seen solid gains, so fresh buyers need to think carefully about what is now priced in. Large ongoing investments in U.S. manufacturing facilities and collaborations in diagnostics can support expectations for future cash flows, while the...

Roper Technologies has underperformed the market, while analysts remain moderately optimistic on its future prospects.

Roper Technologies (NASDAQ:ROP) is pursuing a strategy centered on long-term free-cash-flow-per-share growth, portfolio collaboration and acquisitions of vertical-market software businesses, while increasingly deploying artificial intelligence across its operations and products, Chief Financial Offi

Roper's Application Software segment drives growth as SaaS adoption, GenAI innovation and recurring revenues support strong momentum.

Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts see the stock’s long term potential. This move lines up with recent research that highlights contrasting views on the company’s pipeline, from optimism around giredestrant and 2027 catalysts to more cautious takes on how much upside is already captured in forecasts. Read on to see how these shifting assumptions shape the evolving narrative...

Software stocks are staging a comeback in the second half of the year, according to Jefferies analysts, who pointed to strong results from ServiceNow Inc (NYSE:NOW, XETRA:4S0), SAP, Roper Technologies, Atlassian (NASDAQ:TEAM) and Cloudflare as evidence the sector is shaking off fears of...

Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.

Roche Holding (SWX:ROP) has entered a clinical collaboration with Evexta Bio to test a combination of rupitasertib and giredestrant. The partnership focuses on a Phase 1b trial in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. The agreement centers on a breast cancer segment with significant unmet medical need. Roche Holding, traded as SWX:ROP, is adding this collaboration to an oncology portfolio that already plays a central role in the company’s identity. The stock...

DOX vs. ROP: Which Stock Is the Better Value Option?

Roche Holding (SWX:ROP) received FDA clearance for its cobas BV/CV assay for diagnosing bacterial vaginosis and Candida vaginitis in the United States. The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Susvimo, a ranibizumab eye implant, for neovascular age related macular degeneration in Europe. Roche Holding sits at the intersection of pharmaceuticals and diagnostics, which gives the company multiple ways to respond as medical practice...

Moby summary of Roper Technologies, Inc.'s Q2 2026 earnings call

Industrial stocks bucked a falling market on Thursday. The State Street Industrial Select Sector SPDR ETF popped back into in a buy zone, led by gap-ups and breakouts for CSX, RTX and others. Many holdings in this exchange traded fund delivered blowout earnings this week.

Roper Technologies Inc (ROP) reports a 9% revenue increase and raises full-year DEPS guidance, while navigating AI adoption and cost management challenges.

ROP beats Q2 earnings and revenue estimates, driven by Application Software strength, and raises its 2026 earnings outlook.

Roper Technologies (NASDAQ:ROP) reported second-quarter results that topped its internal expectations and raised its full-year outlook, citing solid organic growth, continued strong retention and accelerating artificial intelligence product development across its portfolio. President and Chief Exec

Stock Market Today: The Dow Jones index dropped 500 points Thursday as Alphabet and Tesla stock dived on earnings. Oil prices jumped.

The headline numbers for Roper Technologies (ROP) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Roper Technologies (ROP) delivered earnings and revenue surprises of +1.70% and +0.50%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Roche Holding (SWX:ROP) has appointed Dan Malarek as President and CEO of Roche Diagnostics North America. The leadership change affects one of Roche’s key operating segments within its broader healthcare business. Malarek previously led Foundation Medicine, a Roche affiliate focused on precision medicine and genomic insights. Roche Holding’s diagnostics arm sits at the center of how the company supports hospitals, labs, and clinicians with testing platforms and data driven tools. As...

CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls

Beyond analysts' top-and-bottom-line estimates for Roper Technologies (ROP), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Roper Technologies' bright outlook, software momentum and acquisition gains outweigh Accenture's AI-related risks and weak bookings.

ROP heads into Q2 results with steady earnings estimates as software strength and the Subsplash acquisition may support revenue growth.

Roper Technologies (ROP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche Holding (SWX:ROP) is back in focus after the US Food and Drug Administration granted Priority Review to its supplemental Biologics License Application for Gazyva/Gazyvaro in primary membranous nephropathy, highlighting late stage pipeline momentum. See our latest analysis for Roche Holding. Roche Holding’s CHF330.2 share price follows a 5.33% 90 day share price return and a 32.83% 1 year total shareholder return, suggesting recent FDA and diagnostics news is feeding into building...

Roche Holding shares have delivered a 35.0% return over the past three years, and the stock now screens as undervalued on market multiples with a high value score, raising the question of whether the current price still offers a margin of safety. A 35.0% gain over three years suggests Roche Holding has already rewarded patient shareholders, so fresh buyers need to consider how much of the story is already reflected in the price. Positive late stage data for oncology and kidney disease...

Roche Holding (SWX:ROP) has introduced the cobas HDV test, described as the first fully automated, high throughput assay for Hepatitis D Virus detection. The test is designed to support improved diagnosis and monitoring of Hepatitis D, which is considered the most aggressive form of viral hepatitis. The launch targets a major unmet clinical need and is intended to support laboratories as new HDV treatments become available. For investors tracking Roche Holding, the cobas HDV launch adds a...